An observational study in Delayed Neurocognitive Recovery, Cardiopulmonary Bypass and Perioperative Neurocognitive Disorders, sponsored by XiaoLiang Wang. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by XiaoLiang Wang · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Neurocognitive Disorders with a site in China — 13 open to participants now, 14 under way, 1 of them phase 3. Neurocognitive Disorders · China.
Among the 22 studies in Neurocognitive Disorders with a site in China, this one is one of 6 that started in 2026, is one of 7 observational ones, reaches primary completion later than 6 of the 13 other live ones, and was the 22nd registered.
275 studies on the registry are indexed under Neurocognitive Disorders; 91 are open to participants now.
Browse Neurocognitive Disorders studies →13 of the 22 studies in Neurocognitive Disorders with a site in China are open now. Recruiting first, the newest first:
Chinese Academy of Medical Sciences, Fuwai Hospital · Sites in China
Ages 60+
Shanghai 10th People's Hospital · Sites in China
Ages 65+
Fujian Provincial Hospital · Sites in China
Ages 60+ · Healthy volunteers
First Affiliated Hospital of Wannan Medical College · Sites in China
Ages 18+
Zhejiang University · Sites in China
Ages 60–80 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 61 Neurocognitive Disorders studies recruiting now, 38 (62%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 150 across 97 observational studies indexed under Neurocognitive Disorders.
Median enrollment 264 across the 15 interventional studies, 210 across the 7 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 22 have an industry lead sponsor. The 10 most frequent:
XiaoLiang Wang is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
XiaoLiang Wang has 1 study filed under Neurocognitive Disorders — fewer than ten, so there is no comparison to draw.
7 of the studies in Neurocognitive Disorders with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06416514Fujian Provincial HospitalPersonalized Interventions Via Health Portraits in Mild Behavioral Impairment | 2026-12-30 |
| NCT07878676Chinese Academy of Medical Sciences, Fuwai HospitalImpact of Preoperative Mild Cognitive Impairment on Postoperative Delirium in Patients Undergoing Cardiac Surgery | 2027-01 |
| NCT07665099Xijing HospitalThe Effect of Esketamine on Postoperative Cognitive Function in Elderly Patients Undergoing Oral and Maxillofacial Surgery | 2027-01-15 |
| NCT07914803Peking University First HospitalIntranasal Dexmedetomidine-esketamine Combination and Postoperative Cognitive Recovery in Older Patients | 2027-06 |
| NCT07936929XiaoLiang WangGut Microbiota and Amino Acid Metabolism in Post-CPB Delayed Neurocognitive Recovery | 2027-08-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 22 studies in Neurocognitive Disorders with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Delayed neurocognitive recovery (dNCR) is a common neurological complication in adult patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). Emerging evidence suggests that CPB-associated hypoperfusion and perioperative stress remodel the gut microbiome and impair intestinal barrier integrity, which may contribute to neuroinflammation and cognitive decline via the gut-brain axis. This prospective observational cohort study aims to investigate the longitudinal trajectories of the gut metagenome (specifically focusing on Holdemanella biformis and amino acid metabolic functions), fecal and plasma metabolites (L-lysine, L-tryptophan, tryptophanol, and short-chain fatty acids), and plasma markers of intestinal barrier injury (I-FABP) and endotoxin response (LBP) from pre-operation (T0) to post-operation (T2) in adult CPB patients, and to evaluate their associations with postoperative dNCR and domain-specific cognitive changes.
Adult patients (aged 18 years or older) scheduled for elective cardiac surgery under cardiopulmonary bypass (CPB) will be prospectively enrolled. Comprehensive neuropsychological assessments covering global cognition (MoCA), learning and memory (HVLT or RAVLT), executive function (Trail Making Test B), and attention/processing speed (Digit Span and Digit Symbol tests) will be conducted at baseline (T0: 1 to 3 days before surgery) and postoperatively (T2: 5 to 10 days after surgery or before hospital discharge). Postoperative delirium will be screened daily using CAM or CAM-ICU. Paired stool and blood samples will be collected at both T0 and T2. Stool samples will undergo shotgun metagenomic sequencing and targeted metabolomics profiling (pre-specified panel: L-lysine, L-tryptophan, tryptophanol, acetate, propionate, and butyrate). Blood samples will be analyzed for intestinal fatty acid-binding protein (I-FABP) and lipopolysaccharide-binding protein (LBP). Linear mixed-effects models and multivariable regression adjusting for age and clinical covariates will be applied to identify time-by-dNCR interaction effects and associations with the continuous global cognitive composite delta-Z score.
Adult patients (aged 18 years or older) admitted to Nanjing First Hospital for elective cardiac surgery requiring cardiopulmonary bypass (CPB).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients aged 18 years or older undergoing elective cardiac surgery with cardiopulmonary bypass (CPB), evaluated longitudinally at T0 (1-3 days preoperatively) and T2 (5-10 days postoperatively or before discharge) for cognitive function, gut microbiome, fecal metabolites, and plasma intestinal injury biomarkers.
Other: Longitudinal Biospecimen Collection and Cognitive Assessment
Observational collection of paired stool and blood samples and administration of neuropsychological test batteries at T0 and T2 during routine perioperative care for cardiac surgery with CPB. No experimental therapeutic intervention is administered.
Change in Global Cognitive Composite Z-Score (Delta-Z)
A composite cognitive Z-score calculated from a neuropsychological test battery assessing learning and memory (Hopkins Verbal Learning Test \[HVLT\] or Rey Auditory Verbal Learning Test \[RAVLT\]), executive function (Trail Making Test Part B \[TMT-B\]), and attention/processing speed (Digit Span and Digit Symbol tests). Individual test change scores (T2 minus T0) are standardized and combined into a global cognitive composite delta-Z score (higher values indicate better cognitive preservation).
Time frame: Baseline (T0: 1 to 3 days before surgery) and Postoperative (T2: 5 to 10 days after surgery or prior to hospital discharge)
Incidence of Delayed Neurocognitive Recovery (dNCR)
Proportion of participants classified as having delayed neurocognitive recovery (dNCR) at T2 based on the reliable change index / pre-specified Z-score decline rules across the neuropsychological battery and Montreal Cognitive Assessment (MoCA).
Time frame: From baseline (T0: 1 to 3 days before surgery) to T2 (5 to 10 days after surgery or prior to hospital discharge)
Changes in Fecal Metagenomic Taxonomic and Functional Profiles
Longitudinal changes in gut microbial community structure, specifically the relative abundance, prevalence, and strain markers of Holdemanella biformis, and KEGG Orthology (KO)/MetaCyc functional modules related to lysine, tryptophan, phosphotransferase system (PTS), and short-chain fatty acid (SCFA) metabolism.
Time frame: Baseline (T0: 1 to 3 days before surgery) and Postoperative (T2: 5 to 10 days after surgery or prior to hospital discharge)
Changes in Fecal Targeted Amino Acid Metabolites and Short-Chain Fatty Acids (SCFAs)
Concentrations of pre-registered fecal metabolites including L-lysine, L-tryptophan, tryptophanol, acetate, propionate, and butyrate quantified at T0 and T2.
Time frame: Baseline (T0: 1 to 3 days before surgery) and Postoperative (T2: 5 to 10 days after surgery or prior to hospital discharge)
Changes in Plasma Intestinal Fatty Acid-Binding Protein (I-FABP) and Lipopolysaccharide-Binding Protein (LBP)
Blood levels of I-FABP (marker of intestinal epithelial injury) and LBP (marker of host endotoxin response) measured by ELISA.
Time frame: Baseline (T0: 1 to 3 days before surgery) and Postoperative (T2: 5 to 10 days after surgery or prior to hospital discharge)
Incidence of Postoperative Delirium (POD)
Assessed daily after surgery using the Confusion Assessment Method (CAM) or CAM for the Intensive Care Unit (CAM-ICU).
Time frame: Postoperative Day 1 through Postoperative Day 7 (or hospital discharge)
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.
Of 53 non-industry observational studies under Neurocognitive Disorders, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 78. This study's planned 11 months is below that.
Counting every sponsor, half of 54 studies reached it within 44 months; a quarter within 20 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
XiaoLiang Wang